Limitations of Guideline‐Recommended Risk Stratification in Identifying <scp>MASLD</scp> Patients for Novel Drug Treatments

Current guidelines recommend FIB-4 and transient elastography for non-invasive risk stratification in metabolic dysfunction-associated steatotic liver disease (MASLD). These tests can predict the presence or absence of advanced fibrosis, but their accuracy for identifying significant fibrosis in MASLD patients eligible for novel drug treatments remains unclear. In a multicenter cohort of 458 biopsy-proven MASLD patients, we evaluated the suitability of FIB-4 for identifying MASLD with histologically significant fibrosis (≥ F2). In a subcohort of 291 patients, we further assessed the diagnostic performance of the guideline-based sequential use of FIB-4 and transient elastography. We demonstrate that the recommended risk stratification remains suboptimal for the identification of patients with significant fibrosis, resulting in remarkably high false-positive and false-negative rates for FIB-4 (43% and 26%, respectively). Consequently, guideline-based risk stratification may misclassify a significant proportion of patients, leading to inappropriate treatment decisions regarding novel MASLD therapies approved for F2/F3 fibrosis.

Authors

Institutions

Publication Details

Journal
Liver International
Published
2025-08-08
DOI
https://doi.org/10.1111/liv.70281
Citations
2
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
2.71

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Limitations of Guideline‐Recommended Risk Stratification in Identifying MASLD Patients for Novel Drug Treatments

Martin Franck, Jan‐Peter Sowa, Monika Rau, Heike Bantel et al.
2 citations
Liver International
Liver Disease Diagnosis and Treatment
2.71
article

Limitations of Guideline‐Recommended Risk Stratification in Identifying MASLD Patients for Novel Drug Treatments

Martin Franck, Jan‐Peter Sowa, Monika Rau, Heike Bantel, Katharina John, Andreas Geier, Münevver Demir, Klaus Schulze‐Osthoff, Heiner H. Wedemeyer, Jörn M. Schattenberg
article en
2 citations

Abstract

Current guidelines recommend FIB-4 and transient elastography for non-invasive risk stratification in metabolic dysfunction-associated steatotic liver disease (MASLD). These tests can predict the presence or absence of advanced fibrosis, but their accuracy for identifying significant fibrosis in MASLD patients eligible for novel drug treatments remains unclear. In a multicenter cohort of 458 biopsy-proven MASLD patients, we evaluated the suitability of FIB-4 for identifying MASLD with histologically significant fibrosis (≥ F2). In a subcohort of 291 patients, we further assessed the diagnostic performance of the guideline-based sequential use of FIB-4 and transient elastography. We demonstrate that the recommended risk stratification remains suboptimal for the identification of patients with significant fibrosis, resulting in remarkably high false-positive and false-negative rates for FIB-4 (43% and 26%, respectively). Consequently, guideline-based risk stratification may misclassify a significant proportion of patients, leading to inappropriate treatment decisions regarding novel MASLD therapies approved for F2/F3 fibrosis.

Liver InternationalVol. 45(9)
German Cancer Research Center (DE), Johannes Gutenberg University Mainz (DE), Heidelberg University (DE), Medizinische Hochschule Hannover (DE), University Medical Center of the Johannes Gutenberg University Mainz (DE), Universitätsklinikum Knappschaftskrankenhaus Bochum (DE), Universitätsklinikum Würzburg (DE), University Hospital Cologne (DE), Charité - Universitätsmedizin Berlin (DE), University of Tübingen (DE), Ruhr University Bochum (DE), Saarland University (DE)
Deutsche Forschungsgemeinschaft, Bundesministerium für Bildung und Forschung
Openalex Percentile: Top 9%
Liver Disease Diagnosis and Treatment
2.71
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.